Relapse and recurrence prevention in major depression: A critical review of placebo-controlled efficacy studies with special emphasis on methodological issues

European Psychiatry

Volumn 16, Issue 6, 2001, Pages 327-335

  Storosum, J G ^a,b   Van Zwieten, B J ^a   Vermeulen, H D B ^b   Wohlfarth, T ^a   Van Den Brink, W ^a  

^a MEDICINES EVALUATION BOARD   (Netherlands)

^b UNIVERSITY OF AMSTERDAM   (Netherlands)

Author keywords

Long term efficacy; Major depression; Methodology; Recurrence; Relapse

Indexed keywords

AMINEPTINE; AMITRIPTYLINE; CITALOPRAM; FLUVOXAMINE; IMIPRAMINE; MAPROTILINE; MIRTAZAPINE; NEFAZODONE; PAROXETINE; PLACEBO; REBOXETINE; SERTRALINE; TRAZODONE; VENLAFAXINE;

ARTICLE; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; DEPRESSION; HUMAN; LONG TERM CARE; MEDICAL RESEARCH; METHODOLOGY; OUTCOMES RESEARCH; PRIORITY JOURNAL; PSYCHOPHARMACOLOGY; PSYCHOTHERAPY; RANDOMIZED CONTROLLED TRIAL; RECURRENT DISEASE; RELAPSE; TREATMENT OUTCOME;

EID: 0034809450     PISSN: 09249338     EISSN: None     Source Type: Journal    
DOI: 10.1016/S0924-9338(01)00587-9     Document Type: Article

References (26)

1. The course of monopolar depression and bipolar psychoses
2. Long-term treatment of depression with nefazodone
3. The time course of nonchronic major depression
4. Sertraline in the prevention of depression
5. Efficacy of venlafaxine and placebo during long-term treatment of depression: A pooled analysis of relapse rates
6. Double-blind placebo-substitution study of nefazodone in the prevention of relapse during continuation treatment of outpatients with major depression
7. Efficacy of amineptine in the prevention of relapse in unipolar depression
8. Three-year outcome for maintenance therapies in recurrent depression
9. Conceptualization and rationale for consensus definitions of terms in major depressive disorder
10. Methodologic issues in maintenance therapy clinical trials
11. Long-term outcome of episodes of major depression: Clinical and public health significance
12. Paroxetine is better than placebo in relapse prevention and the prophylaxis of recurrent depression
13. A 24-week study of 20 mg citalopram 40 mg citalopram and placebo in the prevention of relapse of major depression
14. Report of consensus meeting. Clinical relevance of response and improvement in psychopharmacology. A statement from the European College of Neuropsychopharmacology from an ECNP workshop October 1995
15. Mirtazapine versus amitriptyline in the long-term treatment of depression; a double-blind placebo-controlled study
16. Continuation drug treatment for major depressive episodes: How long-should it be maintained?
17. The definition and operational criteria for treatment outcome of major depressive disorder: A review of the current research literature
18. Optimal length of continuation therapy in depression: A prospective assessment during long-term fluoxetine treatment
19. A prospective test of criteria for response remission relapse recovery and recurrence in depressed patients treated with cognitive behavior therapy
20. Citalopram in doses of 20-60 mg is effective in depression relapse prevention: A placebo-controlled 6 month study
21. Prophylactic efficacy of maprotiline on unipolar depression relapse
22. Increased suicidal risk no argument against placebo-controlled trials in major depression
23. Fluvoxamine prevents recurrence of depression: Results of a long-term double-blind placebo-controlled study
24. Relapse and recurrence of depression. A practical approach for prevention
25. Reboxetine, a unique selective NRI, prevents relapse and recurrence in long-term treatment of major depressive disorder